Selecta Biosciences Inc reports results for the quarter ended in June - Earnings Summary

Cartesian Therapeutics

17/08/2023 12:57

* Selecta Biosciences Inc  SELB.OQ  reported a quarterly
adjusted
loss of 7 cents​​ per share for the quarter ended in June. The
mean expectation of seven analysts for the quarter was for a
loss of 8 cents per share.
    * Revenue fell 86.6% to $5.25 million from a year ago;
analysts
expected $11.09 million. 
    * Selecta Biosciences Inc's reported EPS for the quarter was
a
loss of 7 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Selecta Biosciences Inc shares had fallen by 2.7% this
quarter and lost 3.5% so far this year.
    * The company reported a quarterly loss of $11.39 million.
    * Wall Street's median 12-month price target for Selecta
Biosciences Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 17 at 11:57 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.08          -0.07          Beat
 Mar. 31 2023      -0.09          -0.14          Missed
 Dec. 31 2022      -0.07          0.04           Beat
 Sep. 30 2022      -0.01          -0.05          Missed